🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› California
Clinical trial register · United States · industry-sponsored

Clinical Trials in California

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
California 21 Arkansas 16 Florida 12 Illinois 12 Georgia 10
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sarepta Therapeutics, Inc.5 Edgewise Therapeutics, Inc.2 NS Pharma, Inc.2 REGENXBIO Inc.2 Solid Biosciences Inc.2
State
California21 Arkansas16 Florida12 Illinois12 Georgia10
All 28 states
Target enrolment
to
21 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT07287189Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases
Satellos Bioscience, Inc.
Phase 2
51
California, Colorado, Illinois, Massachusetts, Missouri, Ohio, Washington
2025-12-08
Active, closed
A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)
NCT06817382Duchenne Muscular Dystrophy
Insmed Gene Therapy LLC
Phase 1
12
Arkansas, California, Georgia, New York, Ohio, Tennessee, Virginia
2025-07-22
Active, closed
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
NCT06450639Duchenne Muscular Dystrophy
Hoffmann-La Roche
Phase 2
30
Arkansas, California, Georgia, Michigan, Texas, Virginia
2025-04-04
Recruiting
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
NCT06564974Duchenne Muscular Dystrophy
Catalyst Pharmaceuticals, Inc.
Observational
250
Arizona, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Kansas
2024-09-25
Active, closed
NS-050/NCNP-03 in Boys With DMD (Meteor50)
NCT06053814Duchenne Muscular Dystrophy
NS Pharma, Inc.
Phase 1/2
20
California, Colorado, Illinois, Kansas, Pennsylvania
2024-09-18
By invitation
Long Term Follow-up for RGX-202
NCT06491927Duchenne Muscular Dystrophy
REGENXBIO Inc.
Observational
66
Arkansas, California, Illinois, Texas, Virginia
2024-05-08
Recruiting
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
NCT06138639Duchenne Muscular Dystrophy
Solid Biosciences Inc.
Phase 1/2
60
Arkansas, California, Georgia, Illinois, Missouri, Ohio, Oregon, Pennsylvania
2024-05-06
Active, closed
Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
NCT06100887Duchenne Muscular Dystrophy
Edgewise Therapeutics, Inc.
Phase 2
43
California, Florida, Massachusetts, Missouri, North Carolina, Ohio
2024-03-22
By invitation
An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy
NCT06270719Duchenne Muscular Dystrophy
Sarepta Therapeutics, Inc.
Observational
500
Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana
2024-02-07
Active, closed
Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping
NCT06244082DMD, Duchenne Muscular Dystrophy, Duchenne, Exon 44
Avidity Biosciences, Inc.
Phase 2
39
Arkansas, California, Georgia, Massachusetts, Minnesota, North Carolina, Ohio, Texas
2024-01-22
By invitation
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
NCT05967351Duchenne Muscular Dystrophy
Sarepta Therapeutics, Inc.
Phase 3
400
Arkansas, California, Colorado, Florida, Illinois, Iowa, Maryland, Massachusetts
2023-09-27
Active, closed
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
NCT05881408Duchenne Muscular Dystrophy
Sarepta Therapeutics, Inc.
Phase 3
148
Arkansas, California, Florida, Illinois, Maryland, Massachusetts, Missouri, New York
2023-05-31
Active, closed
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
NCT05693142Duchenne Muscular Dystrophy
REGENXBIO Inc.
Phase 2/3
65
Arkansas, California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas
2023-01-04
Active, closed
A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
NCT05540860Duchenne Muscular Dystrophy
Edgewise Therapeutics, Inc.
Phase 2
76
Arkansas, California, Colorado, Florida, Georgia, Iowa, Kansas, Maryland
2022-10-24
Active, closed
Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)
NCT04687020Duchenne Muscular Dystrophy
NS Pharma, Inc.
Phase 4
9
California, Illinois, North Carolina, Virginia
2021-06-10
Recruiting
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
NCT04626674Duchenne Muscular Dystrophy
Sarepta Therapeutics, Inc.
Phase 1
83
Arkansas, California, Florida, Illinois, Missouri, North Carolina, Ohio, Texas
2020-11-23
Active, closed
Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy
NCT04281485Duchenne Muscular Dystrophy
Pfizer
Phase 3
114
Arkansas, California, Florida, Iowa, Kansas, North Carolina, Pennsylvania, Utah
2020-11-05
Active, closed
Open-label Extension of the HOPE-2 Trial
NCT04428476Duchenne Muscular Dystrophy
Capricor Inc.
Phase 2
13
California, Colorado, Missouri, Ohio, Wisconsin
2020-08-05
By invitation
A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice
NCT06606340Duchenne Muscular Dystrophy
Sarepta Therapeutics, Inc.
Observational
300
Arkansas, California, District of Columbia, Florida, Iowa, Maryland, Missouri, New York
2019-01-07
Active, closed
Microdystrophin Gene Transfer Study in Adolescents and Children With DMD
NCT03368742Duchenne Muscular Dystrophy
Solid Biosciences Inc.
Phase 1/2
12
California, Florida
2017-12-06
Recruiting
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
NCT03373968Duchenne Muscular Dystrophy
Italfarmaco
Phase 2/3
206
California, Connecticut, Florida, Georgia, Iowa, Missouri, Oregon, Pennsylvania
2017-10-24
Rows per page Showing 1–21 of 21
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 September 2026. https://priyalifescience.com/clinical-trials-usa/state/california

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.